Rosuvastatin induced rhabdomyolysis in a low risk patient: A case report and review of the literature

Current Clinical Pharmacology

Volumn 4, Issue 1, 2009, Pages 1-3

  Khan, Fahmi Yousef ^a   Ibrahim, Wael ^a  

^a HAMAD GENERAL HOSPITAL   (Qatar)

Author keywords

Cytochrome P450; Rhabdomyolysis; Rosuvastatin

Indexed keywords

AMLODIPINE; CLOPIDOGREL; CREATINE KINASE; CREATININE; ELECTROLYTE; GLIMEPIRIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYOGLOBIN; NONSTEROID ANTIINFLAMMATORY AGENT; ROSUVASTATIN; SIMVASTATIN; VALSARTAN; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ADULT; CASE REPORT; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIET THERAPY; DRUG EFFICACY; DRUG WITHDRAWAL; ELECTROLYTE BLOOD LEVEL; FATIGUE; FLUID THERAPY; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LABORATORY TEST; LOW DRUG DOSE; MALE; MUSCLE WEAKNESS; MYALGIA; NEUROLOGIC EXAMINATION; OSTEOARTHRITIS; PRIORITY JOURNAL; RETINOPATHY; REVIEW; RHABDOMYOLYSIS; URINE LEVEL; BLOOD; CHEMICALLY INDUCED DISORDER; METABOLISM; MIDDLE AGED; MYOGLOBINURIA; QATAR; URINE;

CREATINE KINASE; CREATININE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; MYOGLOBIN; MYOGLOBINURIA; PYRIMIDINES; QATAR; RHABDOMYOLYSIS; SULFONAMIDES;

EID: 65549113869     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488409787236056     Document Type: Review

References (27)

1. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295: 1556-65.
2. Antons KA, Williams CD, Baker SK, Phillips PS. Clinical perspectives of statin-induced rhabdomyolysis. Am J Med 2006; 119: 400-9.
3. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-1504.
4. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003; 92: 152-160.
5. Schuster H, Barter PJ, Stender S, et al. Effects of switching statins on achievement of lipid goal: Measuring Effective Reductions In Cholesterol Using Rosuvastatin therapY (MERCURY I) study. Am Heart J 2004; 147: 705-712.
6. Stein EA, Amerena J, Ballantyne CM, et al. Long-term efficacy and safety of rosuvastatin 40 mg in patients with severe hypercholesterolemia. Am J Cardiol 2007; 100: 1387-96.
7. Shepherd J, Vidt DG, Miller E, Harris S, Blasetto J. Safety of rosuvastatin: Update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program. Cardiology 2007; 107: 433-43.
8. Brewer HB Jr. Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am J Cardiol 2003; 92: 23-29.
9. Wooltorton E. Rosuvastatin (Crestor) and rhabdomyolysis. CMAJ 2004; 171: 129.
10. Association of Crestor (rosuvastatin) with rhabdomyolysis Dear Health Care Professional letter. Mississauga (ON): Astra Zeneca Canada Inc.; 2004 June 15. Available: http://napra.ca/pdfs/advisories/crestorhc.pdf [accessed 2008 July 28.]
11. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003; 289: 1681-90.
12. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002; 346: 539-40.
13. Heerey A, Barry M, Ryan M, Kelly A. the potential for drug interactions with statin therapy in Ireland. Ir J Med Sci 2000; 169: 176-9.
14. McTaggart F. Comparative pharmacology of rosuvastatin. Atheroscler Suppl 2003; 4: 9-14.
15. White CM. A review of the pharmacologic and pharmaco-kinetic aspects of rosuvastatin. J Clin Pharmacol 2002; 42: 963-70.
16. Simonson SG, Raza A, Martin PD, et al. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 2004; 76: 167-77.
17. Prueksaritanont T, Zhao JJ, Bennett MA, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 2002; 301: 1042-51.
18. Prueksaritanont T, Tang C, Qui Y, Mu L, Subramanian R, Lin JH. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 2002; 30: 1280-7.
19. Schneck DW, Birmingham BK, Zalikowski JA, et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 2004; 75: 455-63.
20. Barry M. Rosuvastatin-warfarin drug interaction [comment]. Lancet 2004; 363: 328.
21. Simonson SG, Martin PD, Warwick MJ, Mitchell PD, Schneck DW. The effect on estrogen and progestin pharmacokinetics in healthy women taking an oral contraceptive. Br J Clin Pharmacol 2004; 57: 279-86.
22. Astra Zeneca Pharmaceuticals LP. Crestor (rosuvastatin calcium) prescribing information: Wilmington, DE; 2003.
23. Culhane NS, Lettieri SL, Skae JR. Rosuvastatin for the treatment of hypercholesterolemia. Pharmacotherapy 2005; 25: 990-1000.
24. Flint OP, Masters BA, Gregg RE, Durham SK. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. Toxicol Appl Pharmacol 1997; 145: 91-98.
25. De Pinieux G, Chariot P, Ammi-Said M, et al. Lipid lowering drugs and mitochondrial function: Effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol 1996; 42: 333-337.
26. Evans M, Rees A. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?. Drug Saf 2002; 25: 649-63.
27. Phillips PS, Haas RH, Bannykh S, et al. for the Scripps Mercy Clinical Research Center. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002; 137: 581-5.